NKGEN BIOTECH, INC.

Highlights NKGen Biotech, Inc.

Equities

NKGN

US65488A1016

End-of-day quote Nasdaq Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
1.67 ^USD	+6.37%		+17.61%	-39.27%

05-23	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	CI
05-20	NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology Annual Meeting	05-23	CI
NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
Top Midday Gainers	05-20	MT
Sector Update: Health Care Stocks Ease Monday Afternoon	05-20	MT
NKGen Biotech Cell Therapy Gets Clearance to Start Phase 2 Clinical Trial in Alzheimer's Disease; Shares Rise	05-20	MT
NKGen Biotech, Inc.?s SNK01 NK Cell Therapy Cleares to Start Phase 2 Clinical Trial in Alzheimer?s Disease	05-20	CI
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	04-29	CI
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	04-18	CI
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	03-25	CI
Exchange-Traded Funds Lower, Equity Futures Flat Pre-Bell Friday	12-29	MT
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease	12-28	CI
NKGen Biotech Gets Canadian Regulator's Clearance to Study NK Cell Therapy for Alzheimer's	12-27	MT
NKGen Biotech Inc. Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	12-27	CI
Nkgen Biotech Presented Phase I Clinical Trial Data At the 16Th Annual Clinical Trials on Alzheimer's Disease Conference	26/10/23	CI
NKGen Biotech Gets FDA Clearance to Start Alzheimer's Disease Trial; Shares Jump	24/10/23	MT
NKGen Biotech, Inc. Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer's Disease	24/10/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW